Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Pancreatic Neoplasms 1Ovarian Diseases 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma 1

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 101liposomal doxorubicin 100Cyclophosphamide 96Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 40Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × NUC-1031 × Clear all
NCT02303912 2021-05-18

ProGem2

Imperial College Healthcare NHS Trust

Phase 1 Completed
25 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03146663 2021-02-21

NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

NuCana plc

Phase 2 Terminated
53 enrolled 19 charts
Gynecologic

Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡